facioscapulohumeral muscular dystrophy Clinical Trials

12 recruitingLast updated: May 11, 2026

There are 12 actively recruiting facioscapulohumeral muscular dystrophy clinical trials across 13 countries. Studies span Not Applicable, Phase 1, Phase 2, Phase 3. Top locations include Rochester, New York, United States, Worcester, Massachusetts, United States, Nijmegen, Netherlands. Updated daily from ClinicalTrials.gov.


facioscapulohumeral muscular dystrophy Trials at a Glance

12 actively recruiting trials for facioscapulohumeral muscular dystrophy are listed on ClinicalTrialsFinder across 6 cities in 13 countries. The largest study group is Not Applicable with 2 trials, with the heaviest enrollment activity in Rochester, Worcester, and Nijmegen. Lead sponsors running facioscapulohumeral muscular dystrophy studies include Centre Hospitalier Universitaire de Nice, Epicrispr Biotechnologies, Inc., and Avidity Biosciences, Inc..

Browse facioscapulohumeral muscular dystrophy trials by phase

Treatments under study

About facioscapulohumeral muscular dystrophy Clinical Trials

Looking for clinical trials for facioscapulohumeral muscular dystrophy? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new facioscapulohumeral muscular dystrophy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about facioscapulohumeral muscular dystrophy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 112 of 12 trials

Recruiting
Phase 1Phase 2

A First-in-human Study of EPI-321 in Facioscapulohumeral Muscular Dystrophy

facioscapulohumeral muscular dystrophy
Epicrispr Biotechnologies, Inc.12 enrolled7 locationsNCT06907875
Recruiting

BetterLife FSHD: A Patient-driven Health and Research Platform

facioscapulohumeral muscular dystrophyMuscular Dystrophy, FacioscapulohumeralFSHD1+8 more
FSHD Society5,000 enrolled1 locationNCT07409142
Recruiting
Phase 3

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD

facioscapulohumeral muscular dystrophyFascioscapulohumeral Muscular DystrophyFacio-Scapulo-Humeral Dystrophy+14 more
Avidity Biosciences, Inc.200 enrolled22 locationsNCT07038200
Recruiting
Phase 1

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

FSHD - Facioscapulohumeral Muscular Dystrophy
Restem, LLC.16 enrolled1 locationNCT07086521
Recruiting

Biomarker Development for Muscular Dystrophies

Becker muscular dystrophyfacioscapulohumeral muscular dystrophyDuchenne Muscular Dystrophy+1 more
Massachusetts General Hospital465 enrolled5 locationsNCT05019625
Recruiting

Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry

facioscapulohumeral muscular dystrophyMyotonic DystrophyMuscular Dystrophy+6 more
University of Rochester3,000 enrolled1 locationNCT00082108
Recruiting
Not Applicable

Personalized Training for People With Rare Neuromuscular Disorders

facioscapulohumeral muscular dystrophyNeuromuscular Diseases (NMD)Charcot Marie Tooth Disease (CMT)+1 more
Oslo University Hospital120 enrolled5 locationsNCT06708468
Recruiting

Ten Year Follow-up in FSHD: the FOCUS 3 Study

FSHD - Facioscapulohumeral Muscular Dystrophy
Radboud University Medical Center200 enrolled1 locationNCT06911190
Recruiting
Not Applicable

An 18-month Prospective Natural History Study to Gain Insight Into FSHD2 Pathophysiology and Disease Progression

Facioscapulohumeral Muscular Dystrophy Type 2
Centre Hospitalier Universitaire de Nice50 enrolled9 locationsNCT06079567
Recruiting

A Registered Cohort Study on FSHD1

Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
Ning Wang, MD., PhD.1,000 enrolled1 locationNCT04369209
Recruiting

The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry

facioscapulohumeral muscular dystrophy
Newcastle University1,018 enrolled1 locationNCT04001582
Recruiting

Paediatric Facioscapulohumeral muscular dystrophy (FSHD) Longitudinal Outcome Study (iFSHD-LOS)

facioscapulohumeral muscular dystrophy
Murdoch Childrens Research Institute30 enrolled1 locationACTRN12621001293853